Prostatype Genomics switches to bi-annual reporting

Companies listed on the Nasdaq First North Growth Market in Stockholm must publish bi-annually and may, but do not have to, publish quarterly reports. Prostatype Genomics AB (publ) has previously published quarterly reports, but the company is now switching to bi-annual reporting.

The reason for the change is to reduce the internal administration and associated costs, which is in line with the company's previously communicated efficiency program. The company will of course keep shareholders in Prostatype Genomics regularly updated via its website regarding commercial and scientific progresses.

The next report will be published on 15 February 2024 and covers the period 1 January to 31 December 2023.

An updated financial calendar is available at 
www.prostatypegenomics.com/financial-calendar/.

For questions, please contact CEO Fredrik Persson at email: fredrik.persson@prostatypegenomics.com.

Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm,
Telephone: +46 (0)8-463 80 00
e-mail: certifiedadviser@penser.se

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.